Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
复制标题
米帕明和丁螺环酮用于停止长期苯二氮卓类药物治疗的惊恐障碍患者。
DOI：
10.1097/01.jcp.0000088907.24613.3f
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Rickels,Karl
中科院分区：
文献类型：
--
作者：
Rynn,Moira;Garcia-Espana,Felipe;Greenblatt,DavidJ;Mandos,LauraA;Schweizer,Edward;Rickels,Karl
在40例符合《精神障碍诊断与统计手册》第三版惊恐障碍标准的患者和停止长期使用苯二氮卓类药物的患者中，比较了丙咪嗪、丁旋环酮或安慰剂的预处理。苯二氮卓类药物平均使用时间为75±64个月，苯二氮卓类药物平均摄入量为25.7±19 mg/d，以地西泮当量表示。我们假设，与安慰剂相比，用丙咪嗪或丁螺环酮进行预处理，可以显著减轻苯二氮卓类药物减量前的焦虑和抑郁症状，从而使减量过程更容易完成。所有三种治疗（丙咪嗪、丁螺环酮和安慰剂）均可通过汉密尔顿焦虑评定量表和汉密尔顿抑郁评定量表的变化来测量焦虑和抑郁症状的减轻。停药严重程度和停药后12周无停药状态在3个治疗组之间均无差异。
Pretreatment with imipramine, buspirone, or placebo was compared in 40 patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria for panic disorder and in patients who were discontinuing long-term benzodiazepine use. The average duration of benzodiazepine use was 75±64 months, and the average benzodiazepine intake expressed as diazepam equivalents was 25.7±19 mg/d. We hypothesized that pretreatment with either imipramine or buspirone, in contrast to pretreatment with placebo, would lead to a significant decrease of symptoms of anxiety and depression before tapering benzodiazepines, thus making the taper process easier to complete. All 3 treatments (imipramine, buspirone, and placebo) caused a reduction in anxiety and depression symptoms as measured by changes in the Hamilton Anxiety Rating Scale and Hamilton Depression Rating Scale. Neither discontinuation severity nor taper-free status 12 weeks posttaper differed between the 3 treatment groups.